Novo Nordisk: The Management of Obesity for Appropriate Individuals: Questions, Answers and Resources

Recently, there has been significant interest in anti-obesity medications (AOMs) from the general public, employers, and access stakeholders. In an effort to provide decision-makers like you with information you may need when considering a weight-management approach for your employees or members, we have created these sample Q&As. The topics covered include:

  • Part 1: Impact of Weight Loss
  • Part 2: AOMs for the Treatment of Obesity or Overweight
    • Section 1: Your Population and AOMs
    • Section 2: The Evolution of AOM Coverage
    • Section 3: Integrating AOMs Into Your Organization’s Weight-Management Approach

Obesity and associated comorbidities are a prevalent and costly chronic condition that can impact the health of your employees and your organization. Novo Nordisk recognizes the challenges in the workplace created by obesity and aims to help employers understand the value of chronic weight management

Latest Posts
Blog
2025 Trends in Employee Benefits
Alison Main, Director at Silicon Valley Employers Forum   As organizations adapt to the changing ...
Read More
Partner News
Novo Nordisk – Think You Know the Truth About Compounded “Semaglutide”?
At Novo Nordisk, patient safety is a top priority.  As the sole manufacturer of FDA-approved ...
Read More
Partner News
Nudge Global: Global Financial Health Pulse – Latest Insights
The financial health pulse reveals a stable global financial health score of 55, with encouraging ...
Read More
Follow SVEF
Scroll to Top

Join the Mailing List

Contact the Team

You must be logged in to fill out this form.

Ad Hoc Survey Request

You must be logged in to fill out this form.